Strategic Advisory Board
DiagnoCure has created a Strategic Advisory Board, which includes prominent colorectal cancer key opinion leaders. Their mandate consists of advising the Company on a number of issues related to Previstage™ GCC and the Company’s commercialization initiatives in the United States.
Stanley R. Hamilton , M.D.
Stanley R. Hamilton, M.D., is Professor and Head of the Division of Pathology and Laboratory Medicine at The University of Texas M.D. Anderson Cancer Center in Houston, Texas, where he holds Frederick F. Becker Distinguished University Chair in Cancer Research. He is a gastrointestinal pathologist with research interests in the molecular genetics and genomics of colorectal neoplasia. Dr. Hamilton received his medical degree from the Indiana University School of Medicine in Indianapolis and served his internship and residency in Pathology and Laboratory Medicine at The Johns Hopkins University School of Medicine and Hospital in Baltimore, Maryland, where he was a faculty member for 19 years before his recruitment to M. D. Anderson Cancer Center in 1998.
He is board certified in Anatomic and Clinical Pathology. His laboratory research activities focus on two main areas of translational applications to the management of patients with GI cancer: identification and application of molecular markers for prognosis of gastrointestinal adenocarcinomas and for prediction of response to therapy, and the etiology and molecular pathogenesis of colorectal neoplasia.
His bibliography includes more than 300 research papers.
Edith Peterson Mitchell , M.D.
Edith Peterson Mitchell, M.D., is Clinical Professor of Medicine and Medical Oncology and Program Leader in Gastrointestinal Oncology at Thomas Jefferson University. In addition, she holds the position of Associate Director of Diversity Programs for the Kimmel Cancer Center at Thomas Jefferson University. Dr. Mitchell received a B.S. in biochemistry from Tennessee State University and her medical degree from the Medical College of Virginia in Richmond.
Dr. Mitchell’s research in pancreatic cancer and other GI malignancies involves new drug evaluation and chemotherapy, development of new therapeutic regimens, chemoradiation strategies for combined modality therapy, patient selection criteria, and supportive care for patients with gastrointestinal cancer. Dr. Mitchell travels nationally and internationally teaching and lecturing on the treatment of gastrointestinal malignancies.
Dr. Mitchell has authored and co-authored more than 100 articles, book chapters, and abstracts on cancer treatment, prevention, and cancer control. As a distinguished researcher, she has received 21 Cancer Research and Principal Investigator Awards, and serves on the National Cancer Institute Review Panel and the Cancer Investigations Review Committee.
Dr. Mitchell was selected for inclusion in America’s Top Oncologists.
Daniel J. Sargent, Ph.D.
Daniel J. Sargent, Ph.D., Professor of Biostatistics and Oncology at the Mayo Clinic, is the Group Statistician for the North Central Cancer Treatment Group and the director of Cancer Center Statistics at the Mayo Clinic Comprehensive Cancer Center. He received his BS, MS, and PhD from the University of Minnesota, and has been at Mayo Clinic since graduating in 1996. He is a member of the US Gastrointestinal Cancer Steering Committee, and co-chaired the Gastrointestinal committee for the NCI Common Data Elements Project.
Dr. Sargent co-chaired a joint NCI-EORTC committee on methodology for tumor marker studies, was a member of the FDA panel on endpoints for colon cancer clinical trials, and currently sits on the US NCI Clinical Trials Advisory Committee, which oversees all cancer clinical trials in the United States. Dr. Sargent is a chair or member of over 20 Data Safety and Monitoring Committees.
Dr. Sargent has published papers on innovative designs for Phase I, II, and III clinical trials as well as advances in survival analysis, meta-analysis, and designs for validating tumor biomarkers. He has authored over 150 peer-reviewed manuscripts, book chapters, editorials, and letters.
Martin R. Weiser, M.D.
Martin R. Weiser, M.D., is Associate Attending Surgeon in the Department of Surgery, Colorectal Service, at the Memorial Sloan-Kettering Cancer Center in New York. In addition, he is Associate Professor of Surgery at the Weill Medical College of Cornell University in New York. Dr. Weiser received a B.S. in biology from the University of Michigan (Ann Arbor) and his medical degree from the Pritzker School of Medicine (University of Chicago). Dr. Weiser holds fellows from the Harvard Medical School (Boston), the Memorial Sloan-Kettering Cancer Center and the Mount Sinai Medical Center, both in New York.
Dr. Weiser’s clinical research focuses on improved staging and methods to predict outcome following cancer surgery. His laboratory research focuses on understanding and targeting mechanisms of tumor spread and metastasis.
Dr. Weiser has served as the Program Chair of the Annual Meeting of the American Society of Colon and Rectal Surgeons. He is a member of the AJCC (American Joint Committee on Cancer) staging committee, which develops the staging system for colorectal cancer, and the NCCN (National Comprehensive Cancer Network) colorectal database committee, as well as a cadre member of the GI committee of the CALGB cooperative group.
Dr. Weiser has co-authored many papers and book chapters on a variety of topics, including laparoscopic surgery, colon and rectal cancers, rare anorectal tumors, staging of cancer, predictors of outcome following surgery, and mechanisms of tumor metastasis.